Skip to main content

Table 3 Association of PCSK9 E670G polymorphism and CAD risk

From: Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population

    CAD (n) Controls (n) Crude OR (95% CI) P Adjusted OR (95% CI) P @
All   AA 567 417 0.819 (0.553–1.212) 0.317 0.838 (0.548–1.280) 0.414
AG + GG 59 53
Gender Male AA 396 220 0.960 (0.564–1.636) 0.882 0.952 (0.541–1.675) 0.864
AG + GG 43 23
Female AA 171 197 1.636 (0.862–3.104) 0.132 0.706 (0.345–1.445) 0.341
AG + GG 16 30
Age ≥ 60 (years) AA 407 268 0.850(0.530–1.365) 0.501 0.790(0.363–1.509) 0.407
AG + GG 44 34
< 60 (years) AA 159 149 0.740(0.363–1.509) 0.407 0.896(0.408–1.970) 0.785
AG + GG 15 19
EH Yes AA 415 244 0.717 (0.437–1.174) 0.186 0.688 (0.406–1.165) 0.164
AG + GG 39 32
No AA 152 173 1.084 (0.566–2.076) 0.808 1.260 (0.586–2.709) 0.554
AG + GG 20 21
DM Yes AA 149 57 0.946 (0.583–1.532) 0.820 0.497 (0.193–1.278) 0.147
AG + GG 14 10
No AA 418 360 0.901 (0.580–1.401) 0.644 0.536 (0.225–1.275) 0.158
AG + GG 45 43
Smoking Yes AA 219 105 1.065 (0.469–2.420) 0.880 1.055 (0.443–2.512) 0.903
AG + GG 20 9
No AA 348 312 0.795 (0.503–1.255) 0.325 0.834 (0.498–1.397) 0.490
AG + GG 39 44
  1. CAD coronary artery disease, OR odds ratio, CI confidence interval
  2. @Aadjustment with age, gender, smoking, EH, DM and lipid profiles